April 10, 2018 / 6:42 PM / 5 months ago

BRIEF-Pfizer Provides Update on Phase 3 Trial of Axitinib

April 11 (Reuters) - Pfizer Inc:

* PFIZER PROVIDES UPDATE ON PHASE 3 TRIAL OF AXITINIB AS ADJUVANT TREATMENT FOR PATIENTS AT HIGH RISK OF RENAL CELL CARCINOMA RECURRENCE AFTER SURGERY

* IN TRIAL, NO NEW SAFETY SIGNALS WERE OBSERVED, AND SAFETY PROFILE WAS CONSISTENT WITH KNOWN PROFILE OF INLYTA IN ADVANCED RCC

* INDEPENDENT COMMITTEE FOR PHASE 3 ATLAS TRIAL OF INLYTA RECOMMENDED STOPPING TRIAL AT A PLANNED INTERIM ANALYSIS DUE TO FUTILITY

* DMC'S RECOMMENDATION BASED ON AXITINIB STUDY FAILING TO DEMONSTRATE A CLEAR IMPROVEMENT IN PRIMARY ENDPOINT

* STUDIES EVALUATING INLYTA IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR VARIETY OF ADVANCED STAGE CANCERS, INCLUDING RCC, TO CONTINUE

* WILL CONDUCT ADDITIONAL ANALYSES ON DATA FROM AXITINIB STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below